Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) Patients

Phase 4

Completed

• Conditions: Atopic Dermatitis
• Interventions: Drug: Pimecrolimus; Drug: Placebo

• Registration Number: NCT00121316
• Lead Sponsor: Novartis

Brief Summary

This study is not being conducted in the United States.

Patients who are intolerant of topical corticosteroids (TCS) have either experienced an adverse event resulting from the use of TCS, or require unacceptable levels of exposure to TCS in order to control their AD. This is of particular concern for patients with recurrent flares on delicate skin areas such as the head and neck.

The purpose of this study is to investigate whether pimecrolimus cream 1%, a non-steroidal anti-inflammatory drug, is efficacious in treating mild to moderate head and neck AD in patients who are intolerant of, or dependent on topical corticosteroids.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-10
• Study Completion: 2005-07
• Study First Submitted: 2005-07-13
• Study First Submitted QC: 2005-07-19
• Study First Posted: 2005-07-21
• Status Verified: 2008-01
• Last Update Submitted: 2008-01-10
• Last Update Posted: 2008-01-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• 12 years of age or older
• Mild to moderate facial AD at screening (facial IGA 2 - 3)
• Patients intolerant of, or dependent on, topical corticosteroids
• Diagnosis of atopic dermatitis by the Hanifin and Rajka criteria
• For female patients, a negative pregnancy test. Women who are pregnant or who are breast-feeding may not be included in the study. Women of child-bearing potential must follow a medically recognized form of contraception.

Exclusion Criteria

At baseline and throughout the study, patients:

• Who have AD on greater than 30% of total body surface area in addition to facial eczema
• Who have concurrent skin disease (e.g. acne) in the study area or active skin infections (active bacterial, viral or fungal infections or infestations, herpes simplex, herpes zoster, chicken pox), or other conditions that may interfere with the evaluation (e.g. generalized erythroderma, Netherton's syndrome)
• Who are immunocompromised (e.g. Lymphoma, AIDS, Wiskott-Aldrich Syndrome) or have a history of malignant disease (with the exception of treated basal-cell carcinoma)
• Who have previously reported poor, no clinical response, or hypersensitivity to topical pimecrolimus cream (Elidel)
• Who have received phototherapy (e.g. UVA, UVB) or systemic therapy (e.g.immunosuppressants, corticosteroids, cytostatics) known or suspected to have an effect on AD within 4 weeks of Visit 2
• Who have received investigational drugs within 8 weeks of first application of study drug or planned use of other investigational drugs during participation of this study
• Who are unlikely to comply with therapy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1	Pimecrolimus	Pimecrolimus
2	Placebo	Matching vehicle cream (placebo)

Primary Outcome Measures

Name	Time	Method
The percentage of patients who have a facial Investigator's Global Assessment (IGA) score of 0 or 1 (clear or almost clear)

Secondary Outcome Measures

Name	Time	Method
Percentage of responders in overall Eczema Area and Severity Index (EASI) score
Percentage of responders in the head and neck EASI score
Percentage of patients achieving at least a 60 % reduction from baseline in the head and neck EASI score
Percentage of patients achieving a score of 0 or 1 for the pruritus score (absent or mild)
Effects on skin atrophy and telangiectasia (spider veins) existing at baseline

Trial Locations

Locations (1)

This study is not being conducted in the United States; 🇨🇭 Novartis Pharma AG, Switzerland